Gilead Sciences, Inc. (GILD)
After hours:
Chart Events
Performance Outlook
| Previous Close | 61.81 |
| Open | 61.47 |
| Bid | 62.02 x 1800 |
| Ask | 62.99 x 3100 |
| Day's Range | 61.27 - 62.43 |
| 52 Week Range | 57.17 - 74.12 |
| Volume | |
| Avg. Volume | 8,062,679 |
| Market Cap | 78.223B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 10.67 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 2.92 (4.68%) |
| Ex-Dividend Date | Jun 14, 2022 |
| 1y Target Est | N/A |
- News Direct
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
FOSTER CITY, Calif., June 29, 2022 /3BL Media/ - The U.S. Supreme Court delivered a decision in Dobbs v. Jackson Women’s Health Organization, which overturned the landmark 1973 Roe v. Wade ruling. ...
- News Direct
Gilead Leadership Organization of Black Employees (GLOBE) Raised the Juneteenth Flag
In advance of Juneteenth, our Gilead Leadership Organization of Black Employees (GLOBE) employee resource group gathered to raise the Juneteenth flag on our Foster City campus. With this symbol of ...
- Business Wire
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
SANTA MONICA, Calif., June 28, 2022--Kite, a Gilead Company (Nasdaq: GILD), today announces that the European Commission (EC) has approved its CAR T-cell therapy Yescarta® (axicabtagene ciloleucel) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after three or more lines of systemic therapy. Yescarta has maintained orphan medicinal product designation in this indication.
